(Alliance News) - Evgen Pharma PLC on Friday said it has received all approvals to trial a treatment for acute respiratory infections.
Shares in Evgen Pharma were up 7.5% at 13.30 pence each in London.
The clinical stage drug development company said STAR is a phase II/III trial to investigate whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected Covid-19. SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection.
Evgen said no additional financing will be required as the costs of providing SFX-01 for the trial are not material. Trial recruitment is expected to commence around the end of October.
Chief Executive Officer Huw Jones said: "Receiving full regulatory approval is a significant step forward for us. We look forward to the start of recruitment for the trial shortly with our partner. We hope that the outcome of this trial will lead to an additional treatment for Covid-19 patients and that SFX-01 could play a big part in managing the current pandemic."
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Evgen Pharma (EVG)